Profound Medical (TSE:PRN) has released an update.
Profound Medical’s TULSA procedure is gaining traction as a mainstream treatment for a wide range of prostate diseases, as evidenced by 25 scientific presentations at major medical meetings globally in 2024. The TULSA-PRO system offers a non-invasive, incision-free therapy that shows promise in preserving patients’ urinary continence and sexual function while effectively treating prostate tissue. This innovative technology has secured regulatory approval, including FDA 510(k) clearance, and is supported by positive clinical trial data and real-world reports from top institutions.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
